Genentech Reports Phase III Divarasib Efficacy Results in Lung Cancer
Genentech said its Phase III KRASCENDO 1 study found investigational divarasib more efficacious than current standard of care in previously treated KRAS G12C-mutated lung cancer.
Genentech, a member of the Roche Group (SIX:RO, ROP; OTC:RHHBY), announced today pivotal results from the Phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhib…